NCT01327859已完成3 期
A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 357
- 主要终点
- Safety and tolerability will primarily be assessed by recording of AEs
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and efficacy of donepezil (Aricept) in Parkinson's Disease (PD) patients with dementia.
详细描述
Patients who complete all 24 weeks of the double-blind study E2020-E044-316 (NCT00165815) will be eligible for the open label extension study. Patients and caregiver/study partner will need to provide additional written informed consent to participate in the open label extension study. Safety and tolerability will be assessed after 4, 8 12, 24, 36 and 52 weeks. Cognition, Global Clinical Function, Activities of Daily Living, and Behaviour will be assessed after 24, and 52 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age range: patients must be aged 40 or over
- •Sex distribution: male and female
- •PD according to UK Brain Bank criteria 40 with good response to levodopa as judged by investigator opinion.
- •Women of child bearing potential must have demonstrated a negative serum beta human chorionic gonadotropin (B-HCG) at the screening visit for the double-blind study (E2020-E044-316)(NCT00165815) and a negative urine test result at the screening visit for the open label extension study, (E2020-E044-318)
- •Completed all 24 treatment weeks of the double-blind study E2020-E044-316 (NCT00165815)and completed assessments.
- •Outpatients, with a responsible and reliable caregiver/study partner
- •Health: generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane); vision (glasses, contact lenses permissible), hearing (hearing aid permissible) and speech sufficient for compliance with testing procedures; must be capable of swallowing the study medication.
- •Written informed consent must be obtained from each patient and his/her caregiver/study partner prior to subjecting the patient or caregiver/study partner to any open label extension study related procedures.
排除标准
- •Pregnant or lactating, women.
- •Women of childbearing potential unless:
- •surgically sterile or
- •must be practicing effective contraception (e.g. abstinence, IUD or barrier method plus hormonal method). These patients must be willing to remain on current form of contraception for the duration of the study, (post menopausal women must be amenorrheic for at least 12 months to be considered of non-child bearing potential).
- •Patients with evidence of other psychiatric/neurological disorders, i.e., stroke, schizophrenia, seizure disorder, head injury with loss of consciousness (for at least 1 hour) within the past year, progressive supranuclear palsy, multisystem atrophy, or dementia complicated by other organic disease.
- •Evidence of clinically significant, active gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease. Evidence of second or third degree heart block. Patients with controlled hypertension (supine diastolic blood pressure (BP) < 95 mmHg), right bundle branch block (complete or partial) and pacemakers may be included in the study.
- •Patients previously treated with centrally active acetylchlinesterase (AChE) inhibitors (e.g., physostigmine, tacrine, metrifonate, galantamine, rivastigmine, donepezil) except the medication in the Aricept double-blind study E2020-E044-316 (NCT00165815).
- •Patients and/or caregivers/study partners who are unwilling or unable to fulfill the requirements of the study.
- •Any condition which would make the patient or the caregiver/study partner, in the opinion of the investigator, unsuitable for the study.
- •Patients with known hypersensitivity to AChE inhibitors.
- •Patients who were non-compliant with the inclusion/exclusion criteria or with the study medication received in the preceding Aricept? double-blind study E2020-E044-316 (NCT00165815).
研究组 & 干预措施
Prior Donepezil 5mg
Experimental
干预措施: Prior Donepezil 5mg (Drug)
Prior Donepezil 10mg
Experimental
干预措施: Prior Donzepezil 10mg (Drug)
Prior Placebo
Placebo Comparator
干预措施: Prior Placebo (Drug)
结局指标
主要结局
Safety and tolerability will primarily be assessed by recording of AEs
时间窗: 52 weeks
次要结局
- To assess the efficacy of open-label donepezil (5-10 mg/day) on cognition (ADAS)(52 weeks)
- To assess the efficacy of open-label donepezil (5-10mg/day) on cognition(MMSE)(52 weeks)
- To assess the efficacy of open-label donepezil (5-10 mg/day) on Global Function (CIBIC)(52 weeks)
- To assess the efficacy of open-label donepezil (5-10 mg/day) on ADLs (DAD and Schwab and England scales)(52 weeks)
- To assess the efficacy of open-label donepezil (5-10 mg/day) on behavior (NPI)(52 weeks)
研究者
相似试验
已完成
2 期
An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine ProphylaxisMigraine HeadacheNCT01146509Eisai Inc.89
已完成
4 期
The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living FacilityMild to Severe Alzheimer's DiseaseNCT00571064Eisai Inc.97
已完成
4 期
EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)Alzheimer's DiseaseNCT00230568Eisai Inc.100
终止
3 期
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10Down SyndromeCognitive DysfunctionNCT00754013Eisai Inc.9
终止
3 期
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17Down SyndromeCognitive DysfunctionNCT00754052Eisai Inc.8